EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency

  • Wooldridge J
  • Heubi J
  • Amaro-Galvez R
 et al. 
  • 5


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Background: EUR-1008 (Zenpep™ [pancrelipase]) is a new, enteric-coated, porcine-derived pancreatic enzyme product (PEP) developed for the treatment of cystic fibrosis (CF) patients with malabsorption associated with exocrine pancreatic insufficiency (EPI). Unlike currently marketed PEPs, EUR-1008 contains the label-claimed lipase content. Safety and efficacy were assessed in younger (< 7 years) and older (≥ 7 years) CF patients with EPI. Methods: Two multicenter studies were conducted: a randomized, double-blind, placebo-controlled, crossover trial in patients ≥ 7 years of age (N = 34) and a supplemental, open-label study in children < 7 years of age (N = 19). Use of any medications altering gastric pH/motility was prohibited during the studies. Outcome measures in the randomized trial included changes in the coefficient of fat absorption (CFA), coefficient of nitrogen absorption (CNA), and signs/symptoms of malabsorption for EUR-1008 vs. placebo. Outcome measures in the supplemental study included safety and response (defined as no steatorrhea and no overt signs/symptoms of malabsorption) to EUR-1008 vs. previous enzyme treatment. Results: In the randomized trial, EUR-1008 treatment compared to placebo resulted in a significantly higher mean CFA (88.3% vs. 62.8%, respectively) and CNA (87.2% vs. 65.7%, respectively) (both p < 0.001) and reduced the incidence of malabsorption signs and symptoms in 32 evaluable patients. In the supplemental study, 11 of 19 patients met the criteria for responder with EUR-1008 at the end of the study vs. 10 of 19 patients at screening (previous PEP), and improvements in clinical symptoms were reported with EUR-1008 treatment. EUR-1008 was safe and well tolerated, and no serious drug-related AEs were reported in either study. Conclusions: EUR-1008 was safe, well tolerated, and effective in CF patients of all ages with EPI-associated malabsorption in two clinical trials. Treatment led to clinically and statistically significant improvements in CFA and CNA in the randomized study, and control of malabsorption and clinical symptoms in both studies. © 2009 European Cystic Fibrosis Society.

Author-supplied keywords

  • NCT00297167
  • abdominal distension
  • abdominal pain
  • abnormal feces
  • adolescent
  • adult
  • article
  • child
  • clinical article
  • clinical feature
  • clinical trial
  • controlled clinical trial
  • controlled study
  • contusion
  • coughing
  • crossover procedure
  • cystic fibrosis
  • decreased appetite
  • diarrhea
  • double blind procedure
  • drug efficacy
  • drug safety
  • drug tolerability
  • enzyme replacement
  • eur 1008
  • feces
  • feces analysis
  • female
  • flatulence
  • headache
  • hemoptysis
  • human
  • incidence
  • lipid
  • lipid absorption
  • malabsorption
  • male
  • metabolic disorder
  • multicenter study
  • nitrogen
  • nutritional disorder
  • open study
  • outcome assessment
  • pancreas exocrine insufficiency
  • pancrelipase
  • patient compliance
  • phase 3 clinical trial
  • placebo
  • preschool child
  • quality of life
  • randomized controlled trial
  • respiratory tract infection
  • satiety
  • school child
  • side effect
  • steatorrhea
  • treatment outcome
  • unclassified drug
  • weight reduction
  • zenpep

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • J L Wooldridge

  • J E Heubi

  • R Amaro-Galvez

  • S R Boas

  • K V Blake

  • S Z Nasr

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free